Well, you lost your $50.00!! I predict no more Neo after around 1/1/2013. And no one will buy them out at least for what they want to be paid!!
As a world leader in diagnostics we will grow through the market changes and emerge as one of the best penny stocks money can buy. Start saving your change now and you could own a controlling interest in this company before you know it. Check the sofa cushions and you can buy 1/2 the company by August.
I think I can, I think I can, I know I can, I know I can, ohhhh no I can't, oh no I can't : Break through the $1.80 @ share price....
Attention Attention You guys are smoking dope...It is not going to change!! Stop telling lies!! In other news, NeoGenomics continues to work with the American Clinical Laboratory Association and the College of American Pathologists to permanently extend the Hospital Technical Component ("TC") Grandfather Clause, which has allowed independent laboratories to bill Medicare directly for the technical component of tests reimbursed under the Medicare Physician Fee Schedule. As a result of recent legislation, this decades-old billing practice is now set to expire on June 30th. Unless it is extended further, NeoGenomics and other pathology labs will be required to begin billing hospitals directly for the technical component of affected tests beginning on July 1st. In commenting on this legislation, Mr. VanOort stated, "In the event the TC Grandfather Clause is not extended further, we anticipate that previously grandfathered hospitals will seek price concessions on the affected services as they will receive little or no corresponding increases in reimbursement from Medicare. In such a scenario, we would expect an approximately 5-8% decrease in our overall average revenue per test beginning in Quarter 3.
